SGMO: Sangamo Therapeutics Inc. Market Capitalization-to-Revenue Ratio

Symbol and logo of brand Sangamo (SGMO)

Sangamo Therapeutics brings together top geneticists equipped with the resources to save lives. However, the business is currently undergoing a sharp model shift toward IT platforms for patent licensing. The price-to-sales ratio helps align these transformations with market value, where the current level is 1.90. This approach confirms the company's status as a pioneer in applying ZFP nucleases to combat severe pathologies.

SGMO sangamo.com Price-to-Revenue Ratio (07/04/2022 - 05/09/2026)

Metric breakdowns and analytics for Sangamo (SGMO)

- market capitalization information:
General company analysis:SGMO - Sangamo
Signature product of Sangamo Therapeutics Inc.

Sangamo Therapeutics (SGMO) monetizes its patents through upfront payments from pharma giants, ensuring a steady revenue stream that determines the business's fundamental value. The price-to-sales ratio, illustrated on the Sangamo Therapeutics (SGMO) P/S chart, measures the premium for future growth, allowing investors to timely identify asset overvaluation or find an entry point during abnormal price fluctuations.

Who Sangamo Therapeutics competes with

TEM (Tempus AI, Inc.) - Market Capitalization-to-Revenue Ratio|Qiagen Group - Market Cap to Revenue|Market Capitalization-to-Revenue Ratio IONS|RGEN - Price-to-Revenue Ratio|Price-to-Revenue Coefficient Avidity Biosciences RNA|CRSP: P/S Multiple|Market Cap to Revenue Ratio WGS|RARE (Ultragenyx Pharma) - P/S Multiple|P/S Multiple Beam Therapeutics Inc.|Price-to-Revenue Ratio Sarepta Therapeutics Inc (SRPT)|Twist Bioscience - Market Cap to Revenue Ratio|10x Genomics Inc - Market Cap to Revenue|NTLA (Intellia Therapeutics, Inc.) - Price-to-Sales Ratio|Stoke Corp - P/S Multiple|BLFS (BioLife) - Market Cap to Revenue Ratio|wavelifesciences.com (WVE) - Price-to-Revenue Ratio|MAZE - Price-to-Revenue Coefficient|SION (Sionna Therapeutics, Inc.) - P/S Multiple|Market Cap to Revenue Prime Medicine Corp (PRME)|P/S Multiple TSHA|P/S Multiple uniQure N.V. (QURE)|Price-to-Revenue Ratio MeiraGTx Holdings plc MGTX|RGNX: Market Cap to Revenue Ratio|Solid Biosciences Inc - P/S Multiple|OCGN - P/S Multiple|PACB: P/S Multiple|BNTC - Price-to-Revenue Coefficient|Price-to-Revenue Ratio Design Therapeutics, Inc.|RCKT: Market Capitalization-to-Revenue Ratio|Market Cap to Revenue FDMT (4D Molecular Therapeutics, Inc.)|Lexeo Therapeutics, Inc. - Market Cap to Revenue Ratio|Price-to-Revenue Ratio Korro Bio, Inc. KRRO|EDIT: Market Cap to Revenue Ratio|SLN - Price-to-Revenue Ratio|Price-to-Revenue Multiple ProQR Therapeutics (PRQR)|CDXS (Codexis Bio) - Market Cap to Revenue|Market Cap to Revenue Ratio NAUT|Price-to-Revenue Ratio metagenomi.co|P/S Multiple Precision BioSciences Inc.|P/S Multiple GBIO|Boundless Bio, Inc. - Market Cap to Revenue Ratio|P/S Multiple XCUR (Exicure, Inc.)|Price-to-Revenue Coefficient Imunon, Inc. (IMNN)|PHIO - Price-to-Revenue Ratio|Market Capitalization-to-Revenue Ratio MBIO (mustangbio.com)|RNAZ: P/S Multiple|Market Cap to Revenue Ratio BNGO|APDN (Applied DNA Corp) - P/S Multiple|BLUE: Market Capitalization-to-Revenue Ratio|Price-to-Revenue Ratio ImmunoPrecise (IPA)|OMGA - Price to Sales|Price-to-Revenue Ratio Singular Genomics OMIC|Market Capitalization-to-Revenue Ratio RGLS|Syros Pharmaceuticals, Inc. - P/S Multiple|Price-to-Revenue Coefficient Telesis Bio Inc. TBIO|TRACON Pharmaceuticals, Inc. (TCON) - Price-to-Revenue Ratio|Unity Biotechnology, Inc - Market Capitalization-to-Revenue Ratio